CEO of Protagonist (NASDAQ: PTGX) makes bona fide share gift

Rhea-AI Filing Summary

Protagonist Therapeutics, Inc. President and CEO Dinesh V. Patel, Ph.D. reported a bona fide gift of 1,460 shares of Common Stock to family and friends. The transaction carried a reported price of $0.00 per share, reflecting that no sale proceeds were received.

Following this gift transfer, Patel directly holds 523,478 shares of Protagonist Therapeutics Common Stock. The filing shows no option exercises or open-market purchases or sales in this transaction, only the non-cash gift disposition.

Insider Trade Summary

1,460 shares gifted

Mixed 1 txn

Insider PATEL DINESH V PH D

Role President and CEO

Type	Security	Shares	Price	Value
Gift	Common Stock	1,460	$0.00	--

Holdings After Transaction: Common Stock — 523,478 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares gifted: 1,460 shares Reported gift price: $0.00 per share Shares held after transaction: 523,478 shares +1 more

4 metrics

Shares gifted 1,460 shares Common Stock bona fide gift on 2026-04-23

Reported gift price $0.00 per share Price for 1,460 gifted shares

Shares held after transaction 523,478 shares Direct Common Stock ownership following gift

Gift transactions count 1 transaction Form 4 transaction summary giftCount

Key Terms

bona fide gift, Common Stock, Form 4

3 terms

bona fide gift financial

"This transaction involves a bona fide gift of securities from the Reporting Person to family and friends."

Common Stock financial

"security_title: "Common Stock" for the reported transaction."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4): transaction reported by the CEO."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PATEL DINESH V PH D

(Last) (First) (Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK CALIFORNIA 94560-1160

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/23/2026		G(1)		1,460	D	$0.00	523,478	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction involves a bona fide gift of securities from the Reporting Person to family and friends.

	/s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D.	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Protagonist Therapeutics (PTGX) CEO report in this Form 4?

The CEO of Protagonist Therapeutics, Dinesh V. Patel, Ph.D., reported a bona fide gift of 1,460 shares of Common Stock. The filing describes this as a non-cash transfer to family and friends, with no sale proceeds and no option exercises involved.

How many Protagonist Therapeutics (PTGX) shares did the CEO gift?

Dinesh V. Patel, Ph.D., gifted 1,460 shares of Protagonist Therapeutics Common Stock. The transaction is coded as a bona fide gift at a reported price of $0.00 per share, indicating no cash consideration changed hands in this disposition.

How many Protagonist Therapeutics (PTGX) shares does the CEO hold after the gift?

After the reported gift transaction, Dinesh V. Patel, Ph.D., directly holds 523,478 shares of Protagonist Therapeutics Common Stock. This post-transaction holding figure comes directly from the Form 4 and reflects his remaining direct ownership position.

Was the Protagonist Therapeutics (PTGX) CEO’s Form 4 a stock sale or a gift?

The Form 4 reflects a bona fide gift, not a market sale. Transaction code G and the footnote both describe a gift of 1,460 shares of Common Stock from the CEO to family and friends, with a reported price of $0.00 per share.

Did the Protagonist Therapeutics (PTGX) CEO receive cash from this Form 4 transaction?

No cash was reported as received in this transaction. The Form 4 lists a transaction price of $0.00 per share for the 1,460 gifted shares, indicating a non-cash, bona fide gift transfer to family and friends rather than an open-market sale.